KK2269 / Kyowa Kirin - LARVOL DELTA

Docetaxel-Induced Immune Activation Shows Antitumor Synergy With the Tumor-Targeted CD40 Agonist KK2269. (PubMed, Cancer Sci) - "Using the immunologically cold B16F10-mouse EpCAM subcutaneously transplanted model, the antitumor effects of KK2269 in combination with clinically approved drugs, including anti-programmed cell death 1 (PD-1) antibody, docetaxel, doxorubicin, oxaliplatin, and gemcitabine were evaluated. The antitumor and immune activation effects of docetaxel+KK2269 were also observed in the immunosuppressive intrahepatic transplantation model. This study provides a rationale for combining a tumor-targeting CD40 agonist, KK2269, with docetaxel for the treatment of PD-1 blockade resistant tumors, including intrahepatic tumors, and supports exploration of this combination strategy in the clinic."

IO biomarker • Journal • Hepatocellular Cancer • Liver Cancer • Oncology • Transplantation • CD40

KK2269, an epithelial cell adhesion molecule-targeted CD40 agonist, stimulates anti-tumor immunity resulting in sustained anti-tumor effect against mouse intrahepatic tumor without hepatotoxicity (AACR 2024) - "In addition, KK2269 in combination with docetaxel showed potent antitumor effect accompanied by T-cell infiltration and activation against the intrahepatic tumor, which has a lower immune infiltration. These results suggest that the combination therapy of KK2269 and docetaxel is promising for metastatic EpCAM-positive tumors."

IO biomarker • Preclinical • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Lung Cancer • Oncology • Solid Tumor • CD40 • IL12B

KK2269, an epithelial cell adhesion molecule-targeted CD40 agonist, demonstrates antitumor effects in combination with standard therapies for NSCLC (AACR 2024) - "Docetaxel is used as a combination therapy with ramucirumab, an anti-VEGF receptor 2 (VEGFR2) antibody, for previously treated advanced NSCLC. Thus, a significant antitumor effect was demonstrated when KK2269 was added to the standard treatment of NSCLC (docetaxel + anti-VEGFR2 antibody) and to docetaxel + anti-PD-1 antibody. Our findings strongly suggest that KK2269 provides improved treatment options for patients with NSCLC."

Combination therapy • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD40

A Study of KK2269 in Adult Participants With Solid Tumors (clinicaltrials.gov) - P1 | N=101 | Recruiting | Sponsor: Kyowa Kirin Co., Ltd. | N=71 ➔ 101 | Trial completion date: Dec 2027 ➔ Mar 2029 | Trial primary completion date: Dec 2027 ➔ Mar 2029

Enrollment change • First-in-human • Monotherapy • Trial completion date • Trial primary completion date • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Study of KK2269 in Adult Participants With Solid Tumors (clinicaltrials.gov) - P1 | N=71 | Recruiting | Sponsor: Kyowa Kirin, Inc.

Combination therapy • Monotherapy • New P1 trial • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor